Accessibility Menu
Cogstate logo

Cogstate(OTC) COGZF

Market Cap$297.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)+536%
5 Year+46%
1 Year+54%
1 Month-7%
$1.75
+0.00%
+0.00Today
Cogstate last closing stock price
MetricPriceDate
Last closeUSD 1.752026-07-24
Cogstate stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-12.06%USD 1.992026-07-09
1 month-7.41%USD 1.892026-06-24
3 month-0.57%USD 1.762026-04-22
Year to date+9.37%USD 1.602025-12-23
1 year+53.89%USD 1.142025-07-24
3 year+82.45%USD 0.962023-07-25
5 year+46.26%USD 1.202021-07-23
Since inception+536.36%USD 0.282010-03-25

Cogstate Financials at a Glance

Market Cap

$297.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$103.45M

Net Income (TTM)

$18.39M

EPS (TTM)

$0.06

P/E Ratio

27.78

Dividend

$0.01

Beta (Volatility)

0.47 (Low)

Price

$1.75

Volume

3,000

Open

$1.75

Previous Close

$1.75

Daily Range

$1.75 - $1.81

52-Week Range

$1.00 - $2.10

Estimated Earnings Date

Aug 18, 2026

COGZF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cogstate

Cogstate Limited is a neuroscience technology firm based in Melbourne, Australia, specializing in digital cognitive assessments and electronic solutions for evaluating clinical outcomes. Established in 1999, the company provides a comprehensive suite of cognitive services to enhance clinical trials and healthcare delivery.

Products and Services
  • Digital cognitive assessments for clinical trials
  • Cognigram, a testing system for cognitive impairment
  • Scientific consulting and data management services
Growth Outlook
  • Recent quarterly revenue reached $26.24 million, indicating strong demand
  • Net income for the latest quarter was $4.62 million, showcasing profitability
  • Return on equity stands at 22.19%, reflecting efficient use of shareholder funds
Financial Highlights
  • Trailing twelve-month revenue of $102.5 million, demonstrating consistent growth
  • Net profit margin of 19.63%, indicating strong operational efficiency
  • Current ratio of 3.96, suggesting robust liquidity position
Cogstate Limited operates in the healthcare information services sector, focusing on enhancing cognitive assessment methodologies. The company's Clinical Trials division supports pharmaceutical and biotechnology firms in accurately measuring the effects of various interventions on cognitive function. The Healthcare division offers tools for early detection of cognitive impairment, which is increasingly vital in aging populations. Recent financial performance highlights a solid growth trajectory, with a notable increase in revenue and profitability. The company’s strong liquidity position, as indicated by a current ratio of 3.96, allows for flexibility in operations and potential investments. The return on equity of 22.19% further emphasizes the effective management of shareholder investments. Cogstate's innovative approach to cognitive assessments positions it well within the expanding healthcare technology market, making it an intriguing option for investors interested in the intersection of neuroscience and digital health solutions.
AI Generated • Jul 3, 2026

Industry

Health Care Technology

Sector

Health Care

Employees

410

CEO

Bradley John O'Connor

Website

www.cogstate.com

Headquarters

Melbourne, VIC 3000, AU

COGZF Financials

Key Financial Metrics (TTM)

Gross Margin

34.73%

Operating Margin

21.31%

Net Income Margin

19.63%

Return on Equity

22.19%

Return on Capital

14.62%

Return on Assets

16.23%

Earnings Yield

3.60%

Dividend Yield

0.75%

Payout Ratio

20.72%

Stock Overview

Market Cap

$297.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

169.92M

Volume

3.00K

Avg. Volume

777.143

Financials (TTM)

Gross Profit

$47.79M

Operating Income

$17.21M

EBITDA

$27.58M

Operating Cash Flow

$21.50M

Capital Expenditure

-$870.27K

Free Cash Flow

$20.63M

Cash & ST Invst.

$34.06M

Total Debt

$716.46K

Cogstate Performance Analysis

Cogstate annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 44,980,356N/A
20232023-06-30USD 40,451,123-10.1%
20242024-06-30USD 43,427,7737.4%
20252025-06-30USD 53,090,85822.3%
Cogstate sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3023.4%
Q22024-12-313.0%
Q42025-06-3025.3%
Q22025-12-31-12.5%
Cogstate annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD 0.04N/A
20232023-06-30USD 0.02-52.5%
20242024-06-30USD 0.0355.9%
20252025-06-30USD 0.0685.1%
Cogstate sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3066.7%
Q22024-12-3112.0%
Q42025-06-3065.2%
Q22025-12-31-29.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$26.24M

+39.3%

Gross Profit

$7.26M

+196.2%

Gross Margin

27.66%

N/A

Market Cap

$297.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.86M

N/A

Employees

160

N/A

Net Income

$4.62M

+120.6%

EBITDA

$5.32M

+165.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$34.06M

+34.9%

Total Debt

$716.46K

+38.0%

Accounts Receivable

$13.71M

+66.9%

Inventory

$0.00

N/A

Long Term Debt

$601.94K

+39268.0%

Short Term Debt

$114.52K

-77.9%

Return on Assets

16.23%

N/A

Return on Invested Capital

21.73%

N/A

Free Cash Flow

$2.54M

+423.3%

Operating Cash Flow

$2.92M

+3919.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EDTXFSpectral Medical Inc
$0.99-0.60%
CLVLFClinuvel Pharmaceuticals Limited
$6.37+0.00%
CMVLFCellectis S.A.
$3.47+12.66%
KSIOFKneat.com, Inc.
$4.61-0.17%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About COGZF

What is the current price of Cogstate?

Cogstate is trading at $1.75 per share.

What is the 52-week range for Cogstate?

Over the past 52 weeks, Cogstate has traded between $1.00 and $2.10.

How much debt does Cogstate have?

As of the most recent reporting period, Cogstate reported total debt of $469.92K.

How much cash does Cogstate have on hand?

Cogstate reported $35.56M in cash and cash equivalents in its most recent financial results.

What is Cogstate’s dividend yield?

Cogstate currently has a dividend yield of 0.75%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services